These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 38589763)

  • 21. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
    Arbyn M; de Sanjosé S; Saraiya M; Sideri M; Palefsky J; Lacey C; Gillison M; Bruni L; Ronco G; Wentzensen N; Brotherton J; Qiao YL; Denny L; Bornstein J; Abramowitz L; Giuliano A; Tommasino M; Monsonego J
    Int J Cancer; 2012 Nov; 131(9):1969-82. PubMed ID: 22623137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
    Giuliano AR; Tortolero-Luna G; Ferrer E; Burchell AN; de Sanjose S; Kjaer SK; Muñoz N; Schiffman M; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 10(0 10):K17-28. PubMed ID: 18847554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients.
    Yu D; Qu P; Liu M
    J Obstet Gynaecol Res; 2021 May; 47(5):1624-1630. PubMed ID: 33754436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genitoanal human papillomavirus infection and associated neoplasias.
    Gross G
    Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia.
    Sehnal B; Dusek L; Cibula D; Zima T; Halaska M; Driak D; Slama J
    J Clin Virol; 2014 Jan; 59(1):18-23. PubMed ID: 24315797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis.
    Di Donato V; Caruso G; Bogani G; Cavallari EN; Palaia G; Perniola G; Ralli M; Sorrenti S; Romeo U; Pernazza A; Pierangeli A; Clementi I; Mingoli A; Cassoni A; Tanzi F; Cuccu I; Recine N; Mancino P; de Vincentiis M; Valentini V; d'Ettorre G; Della Rocca C; Mastroianni CM; Antonelli G; Polimeni A; Muzii L; Palaia I
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?
    Marembo T; Fitzpatrick MB; Dube Mandishora RS
    Intervirology; 2024 Apr; 67(1):55-63. PubMed ID: 38574482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Young women, cervical intraepithelial neoplasia and human papillomavirus: risk factors for persistence and recurrence.
    Frega A; Stentella P; De Ioris A; Piazze JJ; Fambrini M; Marchionni M; Cosmi EV
    Cancer Lett; 2003 Jul; 196(2):127-34. PubMed ID: 12860270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.
    Husein-ElAhmed H
    Int J STD AIDS; 2020 Jun; 31(7):606-612. PubMed ID: 32438856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Specific Types of Human Papiloma Virus in Cervical Intraepithelial Lesions and Cervical Cancer in Macedonian Women.
    Aleksioska-Papestiev I; Chibisheva V; Micevska M; Dimitrov G
    Med Arch; 2018 Feb; 72(1):26-30. PubMed ID: 29416214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
    Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
    Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
    Park IU; Introcaso C; Dunne EF
    Clin Infect Dis; 2015 Dec; 61 Suppl 8():S849-55. PubMed ID: 26602622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.